SLDB241220P15000
- 0.00
- 0.000.00%
Solid Biosciences Newsroom
PepGen Stock Craters 35% on FDA Clinical Hold
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Solid Biosciences Initiated at Outperform by Wedbush
Wedbush Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $16
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
Express News | HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
JMP Securities Initiates Solid Biosciences at Market Outperform With $15 Price Target
JMP Securities Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $15
Buy Rating Affirmed: Solid Biosciences' Strong Potential in Gene Therapy for DMD Highlighted by Innovative Technologies and Attractive Valuation
Solid Biosciences Management to Meet With Piper Sandler
Analysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)
Insider Sale: Chief Technology Officer of $SLDB (SLDB) Sells 2,777 Shares
Solid Biosciences Collaborating With Mayo Clinic to Develop Cardiac Gene Therapies
Express News | Solid Biosciences Announces Collaboration With Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Express News | Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Increased Losses Amid R&D Focus
Solid Biosciences to Present at the Jefferies London Healthcare Conference
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $12
Solid Biosciences Price Target Lowered to $12 From $15 at JPMorgan